UK markets open in 5 hours 23 minutes

Amicus Therapeutics, Inc. (FOLD)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
10.43+0.44 (+4.40%)
At close: 04:00PM EDT
10.43 0.00 (0.00%)
After hours: 04:01PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 2.96B
Enterprise value 3.12B
Trailing P/E N/A
Forward P/E 72.99
PEG ratio (5-yr expected) N/A
Price/sales (ttm)7.38
Price/book (mrq)18.46
Enterprise value/revenue 7.80
Enterprise value/EBITDA -33.84

Trading information

Stock price history

Beta (5Y monthly) 0.76
52-week change 3-17.16%
S&P500 52-week change 323.10%
52-week high 314.57
52-week low 39.70
50-day moving average 311.77
200-day moving average 312.18

Share statistics

Avg vol (3-month) 33.03M
Avg vol (10-day) 32.88M
Shares outstanding 5296.18M
Implied shares outstanding 6296.25M
Float 8222.32M
% held by insiders 10.72%
% held by institutions 1109.72%
Shares short (15 Apr 2024) 431.32M
Short ratio (15 Apr 2024) 412.13
Short % of float (15 Apr 2024) 410.65%
Short % of shares outstanding (15 Apr 2024) 410.60%
Shares short (prior month 15 Mar 2024) 432.4M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin -37.96%
Operating margin (ttm)-3.21%

Management effectiveness

Return on assets (ttm)-6.12%
Return on equity (ttm)-107.04%

Income statement

Revenue (ttm)399.36M
Revenue per share (ttm)1.35
Quarterly revenue growth (yoy)30.60%
Gross profit (ttm)N/A
EBITDA -65.62M
Net income avi to common (ttm)-151.58M
Diluted EPS (ttm)-0.51
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)286.2M
Total cash per share (mrq)0.97
Total debt (mrq)445.06M
Total debt/equity (mrq)277.86%
Current ratio (mrq)2.88
Book value per share (mrq)0.55

Cash flow statement

Operating cash flow (ttm)-69.09M
Levered free cash flow (ttm)-25.89M